US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
AstraZeneca rises Friday, still underperforms market
AstraZeneca PLC AZN shares inched up 0.87% to £109.38 Friday, on what proved to be an all-around great trading session for ...
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Guggenheim lifts AstraZeneca stock target, buy rating on prospects
Guggenheim adjusted its price target on shares of AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), increasing it to GBP13,100 from ...
FiercePharma6h
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
BioPharma Dive56m
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
AstraZeneca price target raised to 13,100 GBp from 12,600 GBp at Guggenheim
Guggenheim raised the firm’s price target on AstraZeneca (AZN) to 13,100 GBp from 12,600 GBp and keeps a Buy rating on the shares. The firm is ...
AstraZeneca lymphoma therapy Calquence gets expanded approval in the U.S.
AstraZeneca (AZN) stock in focus as the U.S. FDA expands approval for its lymphoma therapy Calquence with chemoimmunotherapy ...
BioSpace5h
AstraZeneca Gets Full FDA Approval for CMS-Selected Lymphoma Treatment
The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...